View:
- -------------------------------------------------------------------------------- - -------------------------------------------------------------------------------- SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ---------------- SCHEDULE 14D-1 TENDER OFFER STATEMENT PURSUANT TO SECTION 14(D)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO. 9) ---------------- MCKESSON CORPORATION (NAME OF SUBJECT COMPANY) ECO ACQUISITION CORPORATION A WHOLLY OWNED SUBSIDIARY OF ELI LILLY AND COMPANY (BIDDERS) COMMON STOCK, $2.00 PAR VALUE PER SHARE 581556 10 7 (INCLUDING THE ASSOCIATED RIGHTS) (CUSIP NUMBER OF CLASS OF SECURITIES) (TITLE OF CLASS OF SECURITIES) J.B. KING, ESQ. VICE PRESIDENT AND GENERAL COUNSEL ELI LILLY AND COMPANY LILLY CORPORATE CENTER INDIANAPOLIS, INDIANA 46285 (317) 276-2000 (NAMES, ADDRESSES AND TELEPHONE NUMBERS OF PERSONS AUTHORIZED TO RECEIVE NOTICES AND COMMUNICATIONS ON BEHALF OF BIDDER) WITH A COPY TO: BERNARD E. KURY, ESQ. DEWEY BALLANTINE 1301 AVENUE OF THE AMERICAS NEW YORK, NEW YORK 10019 (212) 259-7400 - -------------------------------------------------------------------------------- - -------------------------------------------------------------------------------- This Amendment No. 9 to the Schedule 14D-1 relates to a tender offer by ECO Acquisition Corporation (the "Purchaser"), a Delaware corporation and a wholly owned subsidiary of Eli Lilly and Company, an Indiana corporation ("Parent"), to purchase all outstanding shares of common stock, par value $2.00 per share and the associated Rights (as defined in the Offer to Purchase) (collectively, the "Shares"), of McKesson Corporation (the "Company"), a Delaware corporation, at a purchase price of $76.00 per Share, net to the seller in cash, without interest, upon the terms and subject to the conditions set forth in the Offer to Purchase, dated July 15, 1994 (the "Offer to Purchase"), and the related Letter of Transmittal (which together constitute the "Offer"), copies of which were attached as Exhibits (a)(1) and (a)(2), respectively, to the Schedule 14D- 1 filed with the Securities and Exchange Commission on July 15, 1994 as amended by Amendment Nos. 1, 2, 3, 4, 5, 6, 7 and 8 thereto dated July 27, 1994, August 10, 1994, September 7, 1994, September 21, 1994, October 11, 1994, October 13, 1994, October 14, 1994 and October 24, 1994, respectively (collectively, the "Schedule 14D-1"). The purpose of this Amendment No. 9 is to amend and supplement Items 10 and 11 of the Schedule 14D-1 as described below. ITEM 10. ADDITIONAL INFORMATION TO BE FURNISHED. Reference is made to the press release issued by Parent on October 26, 1994, a copy of which is filed as Exhibit (a)(27) to the Schedule 14D-1 and is incorporated herein by reference. ITEM 11. MATERIAL TO BE FILED AS EXHIBITS. (a)(27) --Form of press release issued by Parent on October 26, 1994. 1 SIGNATURE AFTER DUE INQUIRY AND TO THE BEST OF ITS KNOWLEDGE AND BELIEF, EACH OF THE UNDERSIGNED CERTIFIES THAT THE INFORMATION SET FORTH IN THIS STATEMENT IS TRUE, COMPLETE AND CORRECT. Eli Lilly and Company /s/ James M. Cornelius By: _________________________________ Name: James M. Cornelius Title: Vice President, Finance and Chief Financial Officer ECO Acquisition Corporation /s/ Charles E. Schalliol By: _________________________________ Name: Charles E. Schalliol Title: President Dated: October 26, 1994 2
EXHIBIT (A)(27) OCTOBER 26, 1994 FOR RELEASE IMMEDIATELY REFER TO (317) 276-3655 LILLY EXTENDS HART-SCOTT-RODINO WAITING PERIOD FOR MCKESSON TENDER OFFER Eli Lilly and Company announced today that it has agreed to extend the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act in connection with its tender offer for McKesson Corporation until Thursday, November 3, 1994. The waiting period, as previously extended, was scheduled to expire on October 27, 1994. Lilly said its discussions with the Federal Trade Commission (FTC) were progressing, and that Lilly was hopeful that it will complete the FTC clearance process by November 3. However, no assurance can be given that this will occur. For this reason, as well as to permit McKesson time to complete the previously announced distribution of stock of a newly formed McKesson corporation to its stockholders, it may be necessary to further extend Lilly's offer to purchase the common stock of McKesson, which is currently scheduled to expire on Monday, November 7, 1994.